About
Monoclonal antibody therapy, bispecific antibodies, and fusion proteins
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyChina
Clinical Trials (13)
View allTotal Trials
13
As Lead Sponsor
13
As Collaborator
0
Total Enrollment
1,564
By Phase
PHASE2: 3PHASE3: 1PHASE1/PHASE2: 1PHASE1: 8
By Status
COMPLETED: 5RECRUITING: 4UNKNOWN: 4
Clinical Trials Pipeline13 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06592274Lead Sponsor
A Phase 2 Study of HB0017 in Psoriasis Patients
PHASE2Recruiting
200 participants
Started: Sep 30, 2024 · Completed: Jan 30, 2026
NCT06477237Lead Sponsor
Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
PHASE3Recruiting
400 participants
Started: Mar 1, 2024 · Completed: Dec 31, 2025
NCT06758557Lead Sponsor
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
PHASE1/PHASE2Recruiting
282 participants
Started: Jan 31, 2024 · Completed: Feb 28, 2026
NCT06222125Lead Sponsor
A Study of HB0025 Injection in Patients With Advanced Renal Cancer
PHASE2Recruiting
100 participants
Started: Jan 30, 2023 · Completed: Dec 30, 2025
NCT05531682Lead Sponsor
A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
PHASE2Completed
160 participants
Started: Oct 25, 2022 · Completed: Jan 4, 2024
Locations (1)
Headquarters
Shanghai, China
Map
Loading map...